Navigation Links
MaxCyte to Present at BIO-Europe Spring 2008 Conference
Date:4/7/2008

GAITHERSBURG, Md., April 7, 2008 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Anthony Recupero, Ph.D., Vice President Business Development at MaxCyte, will present on Tuesday, April 8, 2008, at 2:00PM at the BIO-Europe Spring 2008 Conference in Madrid, Spain. Dr. Recupero's presentation will discuss the development of engineered cell based therapies in the context of clinical experiences in cardiopulmonary diseases and novel approaches to cancer immunotherapy as well as drug delivery.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology provides safety, scalability and reproducibility capabilities which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
4. Prometic to present at the American Chemical Society
5. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
6. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
7. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
8. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
9. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
10. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
11. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 Oramed Pharmaceuticals Inc. ... www.oramed.com ), a clinical-stage pharmaceutical ... delivery systems, announced today that Dr. Miriam ... a presentation titled, "Oral Insulin for Diabetes Treatment: ... Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... , ... March 21, 2017 , ... ... biologics. To acquire information on the desired increase and/or decrease in antibody-dependent cellular ... for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, ...
Breaking Biology Technology:
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):